RobertEMartellMD

PubMed

• 5 citations
  VISTA expression and patient selection for immune-based anticancer therapy.
  Alexander S Martin, Michael Molloy, Andrey Ugolkov, Reinhard W von Roemeling, Randolph J Noelle, Lionel D Lewis, Melissa Johnson, Laszlo Radvanyi, Robert E Martell> ;Frontiers in Immunology. 2023 Jan 1
• Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer.
  Zhang, Y., Chen, X., Wang, H., Gordon-Mitchell, S., Sahu, S., Bhagat, T., Choudhary, G., Aluri, S., Pradhan, K., Sahu, P., Carbajal, M., Zhang, H., Agarwal, B., Shastr...> ;Journal of Hematology & Oncology. 2022 Jul 26
• 2 citations
  Association between medication adherence and non-drug healthcare utilisation and costs: a retrospective longitudinal cohort study among US women age 65 and older.
  Siyu Ma, Donald S Shepard, Grant A Ritter, Robert E Martell, Cindy Thomas> ;BMJ Open. 2021 Dec 7
• 15 citations
  Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker a...
  Daniel J. Landsburg, Stefan K. Barta, Radhakrishnan Ramchandren, Connie Lee Batlevi, Swaminathan P. Iyer, Kevin R. Kelly, Ivana N. Micallef, Sonali M. Smith, Don A. St...> ;British Journal of Haematology. 2021 Aug 2
• 4 citations
  Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence
  Siyu Ma, Donald S. Shepard, Grant A. Ritter, Robert E. Martell, Cindy Parks Thomas> ;Plos One. 2021 May 18
• 2 citations
  The First Study Evaluating the Safety of Pre-Surgery Administration of Metformin in Patients with Colorectal and other Gastrointestinal Cancers and Effect on Cancer St...
  Muhammad Wasif Saif, Shrikar Rajagopal, Jennifer Caplain, Martin D. Goodman, Daniel A. Popowich, Bruce A. Orkin, Philip N. Tsichlis, Robert E. Martell> ;Cancer Medicine Journal. 2021 Feb 19
• 8 citations
  The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer
  Siyu Ma, Donald S. Shepard, Grant A. Ritter, Robert E. Martell, Cindy Parks Thomas> ;Cancer. 2020 Aug 1
• 4 citations
  Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Mali...
  Amandeep Godara, Nauman S Siddiqui, Hilal Hachem, Philip N. Tsichlis, Robert E. Martell, Muhammad Wasif Saif> ;Journal of Cellular Signaling. 2020 Jan 1
• 14 citations
  A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors
  Mohammad Wasif Saif, Shrikar Rajagopal, Jennifer Caplain, Elizabeth Grimm, Oksana B. Serebrennikova, Madhumita Das, Philip N. Tsichlis, Robert E. Martell> ;Cancer Chemotherapy and Pharmacology. 2019 Oct 3
• Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Response.
  Jessica K. Paulus, Christina D. Williams, Furha I. Cossor, Michael J. Kelley, Robert E. Martell> ;Cancer Epidemiology, Biomarkers & Prevention. 2017 May 15
• 33 citations
  Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer.
  Jessica K. Paulus, Christina D. Williams, Furha I. Cossor, Michael J. Kelley, Robert E. Martell> ;Cancer Epidemiology, Biomarkers & Prevention. 2016 Jan 1
• 44 citations
  Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
  Igor Puzanov, Jeffrey A. Sosman, Armando Santoro, Muhammad Wasif Saif, Laura W. Goff, Grace K. Dy, Paolo Andrea Zucali, Julie Means-Powell, Wen Wee Ma, Matteo Simonell...> ;Investigational New Drugs. 2015 Feb 1
• 47 citations
  Diabetes, metformin use, and colorectal cancer survival in postmenopausal women
  Furha I. Cossor, Lucile L. Adams-Campbell, Rowan T. Chlebowski, Marc J. Gunter, Karen C. Johnson, Robert E. Martell, Anne McTiernan, Michael S. Simon, Thomas E. Rohan,...> ;Cancer Epidemiology. 2013 Oct 1
• 13 citations
  Discovery of novel drugs for promising targets.
  Robert E. Martell, David G. Brooks, Yan Wang, Keith M. Wilcoxen> ;Clinical Therapeutics. 2013 Sep 1
• 24 citations
  Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration
  Robert E. Martell, David Sermer, Kenneth A. Getz, Kenneth I. Kaitin> ;The Oncologist. 2013 Jan 1
• 41 citations
  MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma
  Robert J. Amato, Joe Stephenson, Sebastien J. Hotte, John Nemunaitis, Karl Bélanger, Gregory K. Reid, Robert E. Martell> ;Cancer Investigation. 2012 May 10
• 141 citations
  Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
  Anas Younes, Yasuhiro Oki, R Gregory Bociek, John Kuruvilla, Michelle A. Fanale, Sattva S. Neelapu, Amanda Copeland, Daniela Buglio, Ahmed Galal, J. M. Besterman, Zuom...> ;The Lancet. Oncology. 2011 Dec 1
• Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is...
  Martell RE, Chiorean EG, Youssoufian H, Rutstein MD, Pytowski B, Benjamin L, Abad L, Patel J, Steele T, Dowd M, Qin A, Kukel CF, Fox FE, Dontabhaktuni A, Morozov A> ;J. Clin. Oncol.. 2011-05-20
• Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.
  Adjei AA, Sosman JA, Martell RE, Dy GK, Goff LW, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, Schwartz BE, Puzanov I> ;J. Clin. Oncol.. 2011-05-20
• 40 citations
  The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
  Daniela Buglio, Vidya Mamidipudi, Noor M. Khaskhely, Helen Brady, Carla Heise, Jeffrey M. Besterman, Robert E. Martell, Kyle J. MacBeth, Anas Younes> ;British Journal of Haematology. 2010 Nov 1
• 91 citations
  Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
  Kristie A. Blum, Anjani Advani, Louis Fernandez, Richard van der Jagt, Joseph Brandwein, Suman Kambhampati, Jeannine Kassis, Melanie E. Davis, Claire Bonfils, Marja Du...> ;British Journal of Haematology. 2009 Nov 1
• Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101).
  Kollmannsberger CK, Hurwitz H, Vlahovic G, Maroun C, Dumouchel J, Reid G, Martell R, Shapiro G> ;J. Clin. Oncol.. 2009-05-20
• Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265-102).
  Hong D, LoRusso P, Kurzrock R, Maroun C, Mehran M, Drouin M, Martell R, Wheler J> ;J. Clin. Oncol.. 2009-05-20
• 191 citations
  Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
  Guillermo Garcia-Manero, Sarit Assouline, Jorge E. Cortes, Zeev Estrov, Hagop M. Kantarjian, H. Yang, Willie Newsome, Wilson H. Miller, Caroline Rousseau, Ann Kalita, ...> ;Blood. 2008 Aug 15
• 32 citations
  Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents.
  Oscar Moradei, Arkadii Vaisburg, Robert E. Martell> ;Current Topics in Medicinal Chemistry. 2008 Jun 30
• Join now to see all